开发用于囊性纤维化的吸入性抗生素：当前的挑战与机遇 - Suppr

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities.

作者信息

Nichols Dave P, Durmowicz Anthony G, Field Ann, Flume Patrick A, VanDevanter Donald R, Mayer-Hamblett Nicole

机构信息

1 Cystic Fibrosis Therapeutics Development Network Coordinating Center, Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington.

2 Cystic Fibrosis Foundation, Bethesda, Maryland.

出版信息

Ann Am Thorac Soc. 2019 May;16(5):534-539. doi: 10.1513/AnnalsATS.201812-863OT.

DOI:10.1513/AnnalsATS.201812-863OT

PMID:30658043

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6491060/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc92/6491060/9b9828320e9e/AnnalsATS.201812-863OT_f1.jpg

相似文献

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities.开发用于囊性纤维化的吸入性抗生素：当前的挑战与机遇

Ann Am Thorac Soc. 2019 May;16(5):534-539. doi: 10.1513/AnnalsATS.201812-863OT.

[Antibiotic inhalation in cystic fibrosis. A review of the literature].[囊性纤维化中的抗生素吸入。文献综述]

Monatsschr Kinderheilkd. 1991 Feb;139(2):73-80.

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.囊性纤维化患者吸入妥布霉素的间歇性给药。囊性纤维化吸入妥布霉素研究组。

N Engl J Med. 1999 Jan 7;340(1):23-30. doi: 10.1056/NEJM199901073400104.

Cystic Fibrosis Frequently Asked Questions: Question 4: What is the appropriate duration of therapy for respiratory exacerbations in Cystic Fibrosis patients infected with Pseudomonas aeruginosa?囊性纤维化常见问题：问题4：感染铜绿假单胞菌的囊性纤维化患者呼吸道加重的适当治疗时长是多久？

Paediatr Respir Rev. 2016 Jan;17:60-2. doi: 10.1016/j.prrv.2015.03.004. Epub 2015 Apr 23.

Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.新型吸入性联合抗生素制剂治疗囊性纤维化患者铜绿假单胞菌气道感染

Expert Rev Anti Infect Ther. 2015 Jul;13(7):897-905. doi: 10.1586/14787210.2015.1041925. Epub 2015 Apr 28.

Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.氨曲南吸入溶液治疗囊性纤维化患者铜绿假单胞菌感染有效性的证据。

Ther Adv Respir Dis. 2015 Feb;9(1):16-21. doi: 10.1177/1753465814561624.

Pseudomonas aeruginosa colonization in the upper and lower airways of a child with cystic fibrosis: a father's meticulous approach to successful eradication.一名患有囊性纤维化儿童上下呼吸道中的铜绿假单胞菌定植：一位父亲成功根除该病菌的细致方法。

J Bras Pneumol. 2019 Oct 14;45(6):e20190191. doi: 10.1590/1806-3713/e20190191.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.新型囊性纤维化吸入性抗生素类别的引入与接受多种吸入性抗生素类别的患者患病率变化之间的关联。

J Cyst Fibros. 2015 May;14(3):370-5. doi: 10.1016/j.jcf.2014.11.005. Epub 2014 Dec 11.

Value of inhaled antibiotics in cystic fibrosis patients.吸入性抗生素在囊性纤维化患者中的价值。

Acta Univ Carol Med (Praha). 1990;36(1-4):34-6.

Inhaled aztreonam.吸入性氨曲南。

Nat Rev Drug Discov. 2010 May;9(5):357-8. doi: 10.1038/nrd3170.

引用本文的文献

Unmasking Cystic Fibrosis in Adulthood, a Case Report.成年期隐匿性囊性纤维化病例报告

J Investig Med High Impact Case Rep. 2025 Jan-Dec;13:23247096251334248. doi: 10.1177/23247096251334248. Epub 2025 Apr 11.

Utilization of Inhaled Antibiotics in Pediatric Non-Cystic Fibrosis Bronchiectasis: A Comprehensive Review.吸入性抗生素在儿童非囊性纤维化支气管扩张症中的应用：一项综述

Antibiotics (Basel). 2025 Feb 7;14(2):165. doi: 10.3390/antibiotics14020165.

Insights on Carbohydrate Binding from Profiles of Cystic Fibrosis Isolates Using Multivalent Fluorescent Glycopolymers Bearing Pendant Monosaccharides.利用带有侧链单糖的多价荧光糖聚合物对囊性纤维化分离株进行分析以洞察碳水化合物结合情况

Microorganisms. 2024 Apr 16;12(4):801. doi: 10.3390/microorganisms12040801.

Advances in the Cystic Fibrosis Drug Development Pipeline.囊性纤维化药物研发进展

Life (Basel). 2023 Aug 30;13(9):1835. doi: 10.3390/life13091835.

Preclinical testing of antimicrobials for cystic fibrosis lung infections: current needs and future priorities.抗微生物药物治疗囊性纤维化肺部感染的临床前试验：当前需求和未来重点。

Microbiology (Reading). 2023 Jul;169(7). doi: 10.1099/mic.0.001361.

Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future.囊性纤维化患者的抗生素耐药性：过去、现在与未来

Antibiotics (Basel). 2023 Jan 20;12(2):217. doi: 10.3390/antibiotics12020217.

Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations.可吸入微粒作为干粉制剂中肺部给药系统。

Regen Biomater. 2022 Dec 8;10:rbac099. doi: 10.1093/rb/rbac099. eCollection 2023.

Antibacterial Activity of a Natural Clay Mineral against Complex and Other Bacterial Pathogens Isolated from People with Cystic Fibrosis.一种天然粘土矿物对从囊性纤维化患者中分离出的复杂及其他细菌病原体的抗菌活性。

Microorganisms. 2023 Jan 6;11(1):150. doi: 10.3390/microorganisms11010150.

Role of inhaled antibiotics in the era of highly effective CFTR modulators.在高效 CFTR 调节剂时代吸入抗生素的作用。

Eur Respir Rev. 2023 Jan 11;32(167). doi: 10.1183/16000617.0154-2022. Print 2023 Mar 31.

Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections.药物、药物、药物：囊性纤维化气道感染的当前治疗模式。

J Pediatric Infect Dis Soc. 2022 Sep 7;11(Supplement_2):S32-S39. doi: 10.1093/jpids/piac061.

本文引用的文献

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.抗微生物药物敏感性测试（AST）及相关临床结局在囊性纤维化患者中的应用：系统评价。

J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30.

Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.消除囊性纤维化患者耐甲氧西林金黄色葡萄球菌的持续感染。

J Cyst Fibros. 2019 May;18(3):357-363. doi: 10.1016/j.jcf.2018.07.005. Epub 2018 Aug 18.

Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014.美国囊性纤维化患者中肺部非结核分枝杆菌痰阳性的流行病学：2010-2014 年。

Ann Am Thorac Soc. 2018 Jul;15(7):817-826. doi: 10.1513/AnnalsATS.201709-727OC.

Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study.慢性铜绿假单胞菌感染在囊性纤维化患者中的变化率：一项基于人群的队列研究。

Clin Infect Dis. 2018 Sep 14;67(7):1089-1095. doi: 10.1093/cid/ciy215.

Antimicrobial molecules in the lung: formulation challenges and future directions for innovation.肺部中的抗菌分子：制剂挑战及创新的未来方向。

Future Med Chem. 2018 Mar 1;10(5):575-604. doi: 10.4155/fmc-2017-0162. Epub 2018 Feb 23.

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.持续交替吸入抗生素治疗囊性纤维化患者的慢性铜绿假单胞菌感染

J Cyst Fibros. 2016 Nov;15(6):809-815. doi: 10.1016/j.jcf.2016.05.001. Epub 2016 May 24.

Cystic fibrosis.囊性纤维化。

Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29.

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.囊性纤维化基金会患者登记处。一个国家观察性疾病登记处的设计与方法。

Ann Am Thorac Soc. 2016 Jul;13(7):1173-9. doi: 10.1513/AnnalsATS.201511-781OC.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.美国囊性纤维化基金会和欧洲囊性纤维化协会关于囊性纤维化患者非结核分枝杆菌管理的共识建议。

Thorax. 2016 Jan;71 Suppl 1(Suppl 1):i1-22. doi: 10.1136/thoraxjnl-2015-207360.

Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.一大群年轻囊性纤维化患者肺功能下降的危险因素。

Pediatr Pulmonol. 2015 Aug;50(8):763-70. doi: 10.1002/ppul.23217. Epub 2015 Jun 9.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献